Accuracy of bronchial cytological diagnosis in lung lesions in comparison with histopathology

Goel, Shreya; Yeshvanth, Sunil Kumar; Asnani, Ritu; Juyal, Divya

doi:10.4103/joc.joc_44_22

Cited by 5 publications

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, these methods are quite invasive and can result in difficulties, such as too few specimens or insufficient exfoliated cells for pathological diagnosis. In addition, there is a potential increase in the risk of bleeding (Goel et al 2022). Hence, the use of a polymerase chain reaction to detect MAGE-A11 and MAGE-A12 may support pathological examination in molecular diagnosis.…”

Section: Discussionmentioning

confidence: 99%

Expression of Melanoma Antigen Genes A11 and A12 in Non-Small Cell Lung Cancer

Gondo Mastutik,

Alphania Rahniayu,

Isnin Anang Marhana

et al. 2023

FMI

View full text Add to dashboard Cite

Highlights:1. In this study, new primers designed using the semi-nested polymerase chain reaction (PCR) method were utilized to identify MAGE-A11 and MAGE-A12 expressions in specimens collected from core biopsy, forcep biopsy, and bronchoalveolar lavage.2. The histopathological analysis revealed positive expressions of MAGE-A11 and MAGE-A12 in specimens diagnosed with non-small cell lung cancer (NSCLC) as well as in specimens with no malignant cells. AbstractThe melanoma antigen gene (MAGE) belongs to the group of cancer testis antigens that are exclusively expressed in germ cells but may be re-expressed in cancer cells. The highly expressed MAGE-A subfamily in lung cancer may potentially be a diagnostic and prognostic biomarker. This study aimed to identify MAGE-A11 and MAGE-A12 expressions in lung tumors obtained from core biopsy, forceps biopsy, and bronchoalveolar lavage specimens. A cross-sectional observational study was conducted on 90 patients clinically diagnosed with lung tumors. These patients received core biopsy, forceps biopsy, and bronchoalveolar lavage interventions after ethical approval was obtained. The complementary deoxyribonucleic acid (cDNA) quality was assessed by the polymerase chain reaction (PCR) of glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The assessment was performed to ascertain if all specimens exhibited positive PCR amplification of the GAPDH gene. MAGE-A11 and MAGE-A12 were identified through a semi-nested reverse transcription PCR. The positive results were detected by measuring the PCR products, with MAGE-A11 and MAGE-A12 measuring at base pairs (bp) of 858 and 496 in the first and second rounds, respectively. The expressions of MAGE-A11 and MAGE-A12 were observed in 3 (3.33%) and 40 (44.44%) out of 90 specimens, respectively. The prevalence rate of non-small cell lung cancer (NSCLC) was 31.11% (28/90). Among these cases, 3.57% (1/28) showed the expression of MAGE-A11, while 32.14% (9/28) exhibited the expression of MAGE-A12. Sixty-two (68.89%) out of 90 patients were diagnosed with no tumor cell malignancy. Out of 62 cases, 2 (3.23%) exhibited the expression of MAGE-A11, while 31 (50%) demonstrated the expression of MAGE-A12. MAGE-A11 and MAGE-A12 were detected in NSCLC and in certain specimens with a pathological diagnosis that indicated the absence of malignant cells. In conclusion, MAGE A11 and MAGE A12 have potential markers that can improve the pathological diagnosis of lung cancer. Further investigation is necessary to explore the expression of MAGE-A in correlation with lung cancer progression.

show abstract

Section: Discussionmentioning

confidence: 99%

Expression of Melanoma Antigen Genes A11 and A12 in Non-Small Cell Lung Cancer

Gondo Mastutik,

Alphania Rahniayu,

Isnin Anang Marhana

et al. 2023

FMI

View full text Add to dashboard Cite

show abstract

Diagnostic Accuracy of the WHO System for Reporting Lung Cytopathology: A Retrospective Analysis

Shakthivel,

Ahluwalia,

Ahuja

et al. 2024

Diagnostic Cytopathology

View full text Add to dashboard Cite

BackgroundLung cancer is the leading cause of cancer‐related deaths globally, with early diagnosis crucial for improving survival. The 2023 WHO reporting system for lung cytopathology aims to standardize diagnostic criteria. This study assesses the system's diagnostic accuracy.Materials and MethodsThis retrospective study analyzed 207 respiratory tract cytology samples (bronchoalveolar lavage/bronchial washing and endobronchial ultrasound‐guided transbronchial needle aspiration) from January 2023 to June 2024. Samples were classified into five WHO categories: Nondiagnostic, Benign, Atypical, Suspicious for Malignancy, and Malignant. Histological correlation was performed where available. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and diagnostic accuracy were calculated using histological diagnosis as the reference.ResultsPatients ranged from 27 to 87 years old, with a male‐to‐female ratio of 5.8:1. Sample distribution: Nondiagnostic (3.4%), Benign (63.7%), Atypical (6.3%), Suspicious for Malignancy (16.9%), and Malignant (9.6%). Histological correlation was available for 46.3% of cases. Risk of malignancy (ROM) was 25% for Nondiagnostic, 25.7% for Benign, 44.4% for Atypical, 93.5% for Suspicious for Malignancy, and 100% for Malignant. Highest sensitivity (84.75%) and NPV (74.29%) were achieved when Atypical, Suspicious for Malignancy, and Malignant categories were considered positive for malignancy.ConclusionThe 2023 WHO reporting system for lung cytopathology offers a standardized and accurate diagnostic framework, enhancing patient management. Further studies are recommended to validate these results.

show abstract

Lung cancer outcomes in the elderly: potential disparity in screening

Singh,

Mazzola,

Xie

et al. 2024

European Journal of Cardio-Thoracic Surgery

View full text Add to dashboard Cite

OBJECTIVES To analyze outcomes of lung cancer in the elderly METHODS A retrospective analysis was performed of patients in the National Cancer Database with NSCLC from 2004–2017 grouped into two categories: 70–79 years (A) and 80–90 years (B). Patients with multiple malignancies were excluded. Kaplan–Meier curves estimated the overall survival for each age group based on stage. RESULTS In total, 466,051 patients were included. Less invasive techniques (imaging & cytology) diagnosed cancer as a function of age: 14.6% in A vs 21.3% in B (p < 0.001, SMD 0.175). Clinical stage IA was least common in B (15%) compared to 17.3% in A (p < 0.001, SMD 0.079). Approximately 83.0% in B didn’t receive surgery compared to 70.0% in A (p < 0.001, SMD 0.299). Of the 83.0%, 8.0% were considered poor surgical candidates because of age or comorbidities compared with 6.2% in A (p < 0.001, SMD 0.299) For 71.0% in B, surgery was not the first treatment plan compared to 62.0% in A (p < 0.001, SMD 0.299). Survival curves showed worse prognosis for each clinical and pathologic stage for B compared to A. CONCLUSIONS Patients older than 80 years present less frequently as clinical stage IA, are less commonly offered surgical intervention, and are more frequently diagnosed using less accurate measures. They also have worse outcomes for each stage compared to younger patients.

show abstract

Accuracy of bronchial cytological diagnosis in lung lesions in comparison with histopathology

Cited by 5 publications

References 17 publications

Expression of Melanoma Antigen Genes A11 and A12 in Non-Small Cell Lung Cancer

Expression of Melanoma Antigen Genes A11 and A12 in Non-Small Cell Lung Cancer

Diagnostic Accuracy of the WHO System for Reporting Lung Cytopathology: A Retrospective Analysis

Lung cancer outcomes in the elderly: potential disparity in screening

Contact Info

Product

Resources

About